We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks.com featured highlights include Flowserve, California Resources and Globus Medical
Read MoreHide Full Article
For Immediate Release
Chicago, IL – April 8, 2026 – Stocks in this week’s article are Flowserve Corp. (FLS - Free Report) , California Resources Corp. (CRC - Free Report) and Globus Medical, Inc. (GMED - Free Report) .
U.S. stock markets have had a choppy start to 2026, with investors balancing resilient economic data and AI-driven optimism against higher oil prices, sticky inflation risks, elevated Treasury yields and geopolitical tensions centered on Iran and the Strait of Hormuz. Further, the sharp rise in oil prices tied to the Middle East conflict has added fresh inflationary risks.
Against such a volatile situation, the traditional way of choosing stocks is a good idea. Sales growth provides a more reliable view for evaluating stocks compared with earnings-focused metrics. So, stocks like Flowserve Corp., California Resources Corp. and Globus Medical, Inc. are worth betting on.
Sales growth is one of the clearest measures of a company's underlying momentum. Unlike earnings, which can be influenced by accounting choices or short-term swings in costs, revenues reflect real demand for a company's products and services. Consistent top-line expansion can point to rising market share, a growing customer base, stronger pricing power or successful entry into new markets.
It can also be an early signal of future profit growth. As sales increase, higher volumes can improve operating leverage and create scope for margin expansion. Still, sales growth is most useful when viewed in context. Comparing performance with peers, industry benchmarks, and the broader business cycle helps distinguish durable strength from a temporary boost.
What matters most is the quality of that growth. Recurring demand is far more valuable than one-off gains, heavy discounting or acquisition-led expansion. Companies that can sustain healthy sales growth across different economic environments are often better positioned to generate stable cash flows, reinvest with confidence, strengthen their balance sheets and preserve a longer runway for expansion.
3 Stocks with Solid Sales Growth to Consider
Irving, TX-based Flowserve is a leading manufacturer and aftermarket service provider of comprehensive flow control systems globally. FLS' revenues are sourced from original equipment manufacturing and aftermarket sales and services.
FLS' expected sales growth rate for 2026 is 6.3%. Flowserve sports a Zacks Rank #1 at present.
Headquartered in Long Beach, CA, California Resources is an independent energy and carbon management company focused primarily on California. CRC operates two reportable segments: oil and natural gas, and carbon management, which it brands as Carbon TerraVault.
California Resources' expected sales growth rate for 2026 is 2.8%. CRC currently sports a Zacks Rank #1.
Audubon, PA-based Globus Medical is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. GMED currently has its sales operations distributed across 65 countries worldwide.
GMED's sales are expected to rise 8.7% in 2026. Globus Medical sports a Zacks Rank #1 at present.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Zacks.com featured highlights include Flowserve, California Resources and Globus Medical
For Immediate Release
Chicago, IL – April 8, 2026 – Stocks in this week’s article are Flowserve Corp. (FLS - Free Report) , California Resources Corp. (CRC - Free Report) and Globus Medical, Inc. (GMED - Free Report) .
Buy 3 Sales Growth Stocks as Rising Geopolitical Risk Shakes Markets
U.S. stock markets have had a choppy start to 2026, with investors balancing resilient economic data and AI-driven optimism against higher oil prices, sticky inflation risks, elevated Treasury yields and geopolitical tensions centered on Iran and the Strait of Hormuz. Further, the sharp rise in oil prices tied to the Middle East conflict has added fresh inflationary risks.
Against such a volatile situation, the traditional way of choosing stocks is a good idea. Sales growth provides a more reliable view for evaluating stocks compared with earnings-focused metrics. So, stocks like Flowserve Corp., California Resources Corp. and Globus Medical, Inc. are worth betting on.
Sales growth is one of the clearest measures of a company's underlying momentum. Unlike earnings, which can be influenced by accounting choices or short-term swings in costs, revenues reflect real demand for a company's products and services. Consistent top-line expansion can point to rising market share, a growing customer base, stronger pricing power or successful entry into new markets.
It can also be an early signal of future profit growth. As sales increase, higher volumes can improve operating leverage and create scope for margin expansion. Still, sales growth is most useful when viewed in context. Comparing performance with peers, industry benchmarks, and the broader business cycle helps distinguish durable strength from a temporary boost.
What matters most is the quality of that growth. Recurring demand is far more valuable than one-off gains, heavy discounting or acquisition-led expansion. Companies that can sustain healthy sales growth across different economic environments are often better positioned to generate stable cash flows, reinvest with confidence, strengthen their balance sheets and preserve a longer runway for expansion.
3 Stocks with Solid Sales Growth to Consider
Irving, TX-based Flowserve is a leading manufacturer and aftermarket service provider of comprehensive flow control systems globally. FLS' revenues are sourced from original equipment manufacturing and aftermarket sales and services.
FLS' expected sales growth rate for 2026 is 6.3%. Flowserve sports a Zacks Rank #1 at present.
Headquartered in Long Beach, CA, California Resources is an independent energy and carbon management company focused primarily on California. CRC operates two reportable segments: oil and natural gas, and carbon management, which it brands as Carbon TerraVault.
California Resources' expected sales growth rate for 2026 is 2.8%. CRC currently sports a Zacks Rank #1.
Audubon, PA-based Globus Medical is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. GMED currently has its sales operations distributed across 65 countries worldwide.
GMED's sales are expected to rise 8.7% in 2026. Globus Medical sports a Zacks Rank #1 at present.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2895531/buy-3-sales-growth-stocks-as-rising-geopolitical-risk-shakes-markets
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.